Ficlatuzumab ± Cetuximab in Patients With Pan-Refractory Recurrent or Metastatic HNSCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer
J. Clin. Oncol 2023 Mar 28;[EPub Ahead of Print], JE Bauman, NF Saba, D Roe, JR Bauman, J Kaczmar, A Bhatia, J Muzaffar, R Julian, S Wang, S Bearelly, A Baker, C Steuer, A Giri, B Burtness, S Centuori, C Caulin, R Klein, K Saboda, S Obara, CH ChungFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.